Compare POST & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POST | GRFS |
|---|---|---|
| Founded | 1895 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.0B |
| IPO Year | N/A | 2006 |
| Metric | POST | GRFS |
|---|---|---|
| Price | $101.81 | $8.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $125.33 | $10.15 |
| AVG Volume (30 Days) | ★ 1.1M | 539.6K |
| Earning Date | 02-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 1.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.51 | 0.64 |
| Revenue | $8,158,100,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $5.18 | $5.46 |
| Revenue Next Year | $0.17 | $5.60 |
| P/E Ratio | $18.36 | ★ $17.46 |
| Revenue Growth | 2.97 | ★ 7.31 |
| 52 Week Low | $95.07 | $6.19 |
| 52 Week High | $119.85 | $11.14 |
| Indicator | POST | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 51.33 |
| Support Level | $96.46 | $8.69 |
| Resistance Level | $98.97 | $9.22 |
| Average True Range (ATR) | 2.40 | 0.27 |
| MACD | 0.55 | 0.04 |
| Stochastic Oscillator | 87.51 | 82.59 |
Post Holdings Inc is an consumer packaged goods holding company. It operates in Post Consumer Brands which Includes branded and private label ready-to-eat cereals, Weetabix Includes the businesses of Weetabix Limited, which Post acquired in July 2017 and which produces and distributes branded and private label RTE cereal, hot cereals and other cereal-based food products, Foodservice which Includes egg and potato products in the foodservice and food ingredient channels from the businesses of MFI Holding Corporation, lastly Refrigerated Retail segment Provides refrigerated retail products, inclusive of side dishes, eggs and egg products, sausage, cheese and other dairy and refrigerated products.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.